Search
Cancer Immunotherapy Toxicity Evaluation (CITE) Program
UCSF Health’s new Cancer Immunotherapy Toxicity Evaluation (CITE) Program is a valuable resource for both patient care and provider consults.A Novel Approach Towards a Vaccine for Relapsing Acute Myeloid Leukemia: Q&A with Dr. Karin Gaensler
There is a major clinical unmet need for effective and safe therapies to increase progression-free and overall survival in older individuals with leukemia whose prognosis is grim.UCSF Health Cancer Services Earns National Accreditation from the Commission on Cancer of the American College of Surgeons
The UCSF cancer program has been continuously accredited by the CoC since 1933, demonstrating its commitment to the best outcomes possible for its cancer patients.Scientists Discover a Deadly Brain Cancer’s Hidden Weakness
The difficult-to-treat brain cancer glioblastoma steals a person’s mental faculties as it spreads, yet the tumor’s insidious ability to infiltrate distant networks in the brain could also prove its undoing.UCSF Surgical Oncologists Providing New Treatment Options for Patients with Metastatic Gastrointestinal Cancers
UCSF Health’s surgical oncology team is a Bay Area leader in an innovative chemotherapy infusion pump used to treat patients with widely metastatic colorectal and bile duct cancers that have spread to the liver and are no longer considered operable.Can Lymph Nodes Boost the Success of Cancer Immunotherapy?
New data from a clinical trial show therapies may activate lymph nodes to produce tumor-tackling T cells.First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial.Cardio-Oncology & Immunology: Specialized Cardiovascular Care for Cancer Patients
Led by a multidisciplinary team of specialists and researchers, our program optimizes the cardiovascular health of cancer patients and cancer survivors.Patients With Detectable PSA After Radical Prostatectomy Have Good Long-Term Outcomes, UCSF Researchers Find
Patients with a detectable prostate-specific antigen (PSA) after radical prostatectomy (RP) may have excellent long-term outcomes, according to two retrospective studies conducted by UCSF researchers.UCSF Surgical Oncologists Present Clinical Findings at International Conference
The latest advances in surgical cancer care and research were showcased at the Society of Surgical Oncology’s (SSO) Annual Meeting, the International Conference on Surgical Cancer Care. The meeting was held in Boston, from March 22 – 25, 2023.Advances in Breast Cancer Care: Individualized Screening, Treatments and Follow-Up
Karen Goodwin, DO, covers everything from how to answer patients’ questions on mammogram frequency to how to counsel them on breast cancer prevention.Killing Pancreatic Cancer with T Cells that Turbocharge Themselves
Novel Immunotherapy Pumps Out Cancer-Killing Cytokines Only Inside the TumorBreast Cancer Risk Calculator Can Assess Risk of Advanced Breast Cancer
Upcoming Conference to Focus on Breast Density and Prediction of Advanced and Interval Breast Cancer RiskUCSF and I-SPY 2 Breast Cancer Researchers Develop Newly Redefined Breast Cancer Response Subtypes
Research scientists and statisticians from UC San Francisco have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients.Drug Turns Cancer Gene Into "Eat Me" Flag for Immune System
UCSF-led study shows promising pre-clinical results in killing cancer cells resistant to current KRAS-targeted treatments.“CAR Pooling” Screens Identify Most Effective Cancer Immunotherapy Cells
New approach by UCSF researchers analyzes how well different re-engineered T cells work against cancer.How AI Found the Words to Kill Cancer Cells
Predictive model allows researchers to encode commands for cells to carry out.Enhancing Care for Thoracic Oncology Surgery Patients
Building on a decades-long reputation for innovation in thoracic surgery, UC San Francisco’s Thoracic Surgery and Oncology Clinic has improved the overall experience for patients undergoing lung and esophageal cancer treatment while continuing to maintain strong outcomes.Navigating the Maze of Breast Cancer Guidelines: Efficient Paths to Personalized Screening
To help PCPs address patients’ breast cancer screening concerns, surgeon Shoko Emily Abe, MD, FACS, breaks down the multitude of screening directives and modalities, with a focus on the needs of those at average risk and those with dense breast tissue.Rethinking How Cancer Cells Evade Targeted Therapy
Glioblastomas (GBMs) are incurable brain tumors with a prognosis of about one-and-a half years on average. They are highly resistant to treatment and have defied all attempts at precision therapy.International Hematologic Conference Features UCSF Health Experts
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 64th Annual Meeting and Exposition.UCSF Researchers Uncover New Pathway for Molecular Cancer Drug Therapies
In a study published December 8, 2022 in Science, UCSF researchers Kevin Lou, an MD-PhD student, Luke Gilbert, PhD, and Kevan Shokat, PhD, reveal the discovery of a cellular uptake pathway important for larger molecules.International Conference Features UCSF Breast Cancer Experts
Breast cancer experts from UCSF Health presented new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most prestigious breast cancer conference.Alan P. Venook, MD, Recognized With Luminary Award for Gastrointestinal Cancers
Alan P. Venook, MD, a renowned expert in colorectal and liver cancers, has been announced as one of the winners of the 2022 Luminary Awards in Gastrointestinal (GI) Cancers.